-0.020 (-0.31%)
Range 6.380 - 6.710   (5.17%)
Open 6.670
Previous Close 6.540
Buy Price 6.430
Buy Volume 12
Sell Price 6.750
Sell Volume 31
Volume 800,299
Value -
Measurement Type Value
EPS (USD) -2.032
Trailing EPS (USD) -1.153
NAV (USD) 1.14
Cash In Hand (USD) 2.34
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5.736
Price / Cash In Hand 2.795
Issued & Paid-up Shares 76,610,100
Treasury Shares -
Market Cap (M) 501.03
Par Value (USD) n.a.
Beta - 75 Days 1.512
R-Squared - 75 Days(%) 6.49
Beta - 500 Days 1.244
R-Squared - 500 Days(%) 16.45
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 30 Nov 2021 05:00.
Data powered by
View All Events


Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company�s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company�s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company�s product candidates are OTX-DP and OTX-TP. OTX-DP is in Phase III clinical development for post-surgical ocular inflammation and pain. OTX-TP is in Phase II clinical development for glaucoma and ocular hypertension. These product candidates combine its hydrogel technology with the United States Food and Drug Administration (FDA), approved therapeutic agents with the goal of providing sustained delivery of drug to the eye.

Loading Chart...